TEVA Related Guidance
-
Teva Pharmaceutical (TEVA) Slammed Early on FY13 Warning
-
Teva Pharma (TEVA) Guides FY13 EPS, Revs Below Expectations
-
Teva Pharmaceutical (TEVA) Tops Q3 EPS by 3c; Guides In-Line
-
Teva Pharma (TEVA) Sees Weaker FY12 Sales, EPS
-
Teva Pharma (TEVA) Issue FY12 Outlook; EPS, Revs to Low-End of Street Expectations
-
Teva (TEVA) CEO Issues FY12 EPS, Sales Outlook
-
Teva (TEVA) Cuts FY11 EPS, Sales Outlook on Call
-
Teva (TEVA) Guides FY11 EPS Below the Street, Sales Inline
-
Teva (TEVA) CEO Raises Bottom End of FY10 Outlook on Call
-
Teva (TEVA) Affirms FY10 EPS Outlook
-
Teva (TEVA) Shares Volatile as CEO Comments on Outlook: Sees $31B in Sales, $6.8B in Net Income by 2014
-
Teva Pharma (TEVA) Guides FY09, FY10 Inline With the Street
-
Teva Pharmaceutical (TEVA) Tops Q2 EPS by 3c; Sees 2010 EPS Growth At Least 35%
-
Teva Pharm (TEVA) Tops Q1 EPS by 3c; Optimistic About Remainder of 2009
-
AstraZeneca (AZN) Settles Infringement Suit with Teva (TEVA) Subsidiary; Confirms FY09 EPS Outlook
-
Barr Pharmaceuticals (BRL) Reports Q2 Results; Guides
-
Teva Pharmaceutical (TEVA) Launches Generic Protonix; Raises Guidance
-
Teva Pharmaceutical (TEVA) Misses Q4 EPS Views; Guides
-
Teva Pharmaceutical (TEVA) Tops Q2 EPS by 20c; Guides Higher
-
TEVA Lowers Guidance For Second Qtr
Back to TEVA Stock Lookup
